Cdk4/6 inhibition reprograms mitochondrial metabolism in brafv600 melanoma via a p53 dependent pathway

Abstract

Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitors are being tested in numerous clinical trials and are currently employed successfully in the clinic for the treatment of breast cancers. Understanding their mechanism of action and interaction with other therapies is vital in their clinical development. CDK4/6 regulate the cell cycle via phosphorylation and inhibition of the tumour suppressor RB, and in addition can phosphorylate many cellular proteins and modulate numerous cellular functions including cell metabolism. Metabolic reprogramming is observed in melanoma following standard‐of‐care BRAF/MEK inhibition and is involved in both therapeutic response and resistance. In preclinical mode..